Will the GALLIUM study with obinutuzumab change current practice in first-line FL patients?
Prognostic value of PET-based response assessment in FL: Secondary analysis of the phase III GALLIUM trial
The results of this secondary analysis of the GALLIUM phase III trial indicated that PET is more accurate than CT in evaluating the responses...
ASH 2016 | Primary Results of the GALLIUM Study
The GALLIUM study is a global, multi-center, open-label study comparing the safety profile and efficacy of front-line obinutuzumab (G) or rituximab (R) in combination with chemotherapy
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox every month